| Today’s Big NewsSep 9, 2024 |
| By Angus Liu The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer. |
|
|
|
By James Waldron The study missed the primary endpoint of demonstrating an improvement in pre-bronchodilator forced expiratory volume (FEV), the amount of air that a person can exhale during a forced breath, compared with placebo. |
By Ayla Ellison In this year's Fierce 50 special report, we are highlighting the innovators and leaders who are shaping the future of healthcare, pharma and biotechnology. This year's honorees demonstrate unwavering dedication and creativity, propelling these industries forward. |
By Conor Hale Think Surgical collected its third FDA clearance in as many months, with the latest being a specialized version of its knee replacement system paired with Zimmer Biomet. |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive. 
|
|
By Fraiser Kansteiner Lilly on Monday revealed that it’s slotting 23-year company veteran Lucas Montarce into the finance chief role after the pharma’s previous CFO, Anat Ashkenazi, announced her departure in early June. Montarce, who’s been with the Indianapolis-based drugmaker since 2001, most recently worked as Lilly's president and general manager for the company’s hub in Spain, Portugal and Greece. |
By Darren Incorvaia For those with amputated limbs, skin that never evolved to sustain pressure is now being asked to do so—for example, the end of a residual leg limb outfitted with a prosthetic. Asking this thinner skin to bear weight can lead to wounding and discomfort, and a fear of developing these problems can lead amputees to limit the use of their prosthetics. |
By Darren Incorvaia After overseeing the $4.1 billion sale of radiopharma player RayzeBio to Bristol Myers Squibb, biotech veteran Ken Song, M.D., didn’t take long to set up his next big venture. He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to dominate the T-cell engager market. |
By Angus Liu Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso. |
By Nick Paul Taylor Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd) showed promise in the setting, offering encouragement as a late-stage trial progresses. |
By Zoey Becker A Delaware judge agreed that AstraZeneca's Alexion breached its contract and failed to pay a milestone payment of $130 million tied to the development of a now scrapped autoimmune candidate originally developed by Syntimmune. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
|
Bringing new oncology therapies to market is challenging, but novel, safer treatments are needed. Download the new QPS Oncology white paper to learn more about oncology clinical trials, challenges and solutions. .png)
|
|
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
